Related Experiment Video
Updated: Dec 6, 2025
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Circulating miRNA-23b and miRNA-143 Are Potential Biomarkers for In-Stent Restenosis
Nicolás Saavedra1, Gabriel Rojas1, Jesús Herrera1
1Center of Molecular Biology & Pharmacogenetics, Department of Basic Sciences, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco, Chile.
Abstract:
In-stent restenosis (ISR) is one of the main complications in patients undergoing percutaneous coronary angioplasty, and microRNAs participate in the contractile-to-synthetic phenotypic switch of vascular smooth muscle cells, a hallmark of restenosis development. MicroRNAs (miRNAs) can be released into circulation from injured tissues, enticing a potential role as noninvasive biomarkers. We aimed to evaluate circulating levels of miRNA-23b, miRNA-143, and miRNA-145 as diagnostic markers of ISR. 142 patients with coronary artery disease undergoing successful angioplasty and a follow-up angiography were included. Subjects were classified according to the degree of obstruction at the angioplasty site into cases (≥50%) or controls (<50%). Total RNA was isolated from plasma to quantify circulating miRNAs levels, and the ROC curves were constructed. Among circulating miRNAs assessed, miRNA-23b and miRNA-143 were significantly lower in cases (miRNA-23b: 18.4x10-5 and miRNA-143: 13.7x10-5) than controls (miRNA-23b: 5.2x10-5, p < 0.0001; miRNA-143: 4.0x10-5, p < 0.0001). Plasma levels of miRNA-145 showed no significant differences. The analysis of the ROC curves showed an area under the curve for miRNA-23b of 0.71 (95% CI: 0.62-0.80, p < 0.0001) and 0.69 for miRNA-143 (95% CI: 0.60-0.78; p < 0.0001). Our data suggest that plasma levels of miRNA-23b and miRNA-143 could be useful as noninvasive biomarkers of ISR.
Insights
Lower levels of circulating microRNA-23b and microRNA-143 in plasma may serve as noninvasive biomarkers for diagnosing in-stent restenosis (ISR) after angioplasty.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Biomarker Discovery
Background:
- In-stent restenosis (ISR) is a significant complication following percutaneous coronary angioplasty.
- MicroRNAs (miRNAs) are implicated in vascular smooth muscle cell phenotypic switching, a key process in restenosis.
- Circulating miRNAs released from injured tissues offer potential as noninvasive diagnostic biomarkers.
Purpose of the Study:
- To investigate the diagnostic utility of plasma miRNA-23b, miRNA-143, and miRNA-145 levels for in-stent restenosis (ISR).
- To evaluate circulating miRNA levels as noninvasive biomarkers for ISR detection.
Main Methods:
- A cohort of 142 patients with coronary artery disease undergoing successful angioplasty were analyzed.
- Patients were categorized into cases (≥50% obstruction) and controls (<50% obstruction) based on follow-up angiography.
- Plasma total RNA was isolated to quantify miRNA levels; Receiver Operating Characteristic (ROC) curves were constructed.
Main Results:
- Plasma levels of miRNA-23b and miRNA-143 were significantly lower in patients with ISR compared to controls.
- No significant difference in plasma miRNA-145 levels was observed between cases and controls.
- ROC curve analysis indicated diagnostic potential for miRNA-23b (AUC=0.71) and miRNA-143 (AUC=0.69).
Conclusions:
- Circulating miRNA-23b and miRNA-143 show promise as noninvasive biomarkers for diagnosing ISR.
- These miRNAs could aid in the early detection and management of in-stent restenosis.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs